111, Inc.
NASDAQ Global MarketRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- 111, Inc. (NASDAQ: YI) operates a leading integrated online and offline healthcare platform in China, digitally connecting patients with pharmaceutical products and healthcare services through its B2C and B2B segments. The company offers online retail pharmacy services via 1 Drugstore, providing prescription drugs, over-the-counter medications, health and wellness products, and medical devices to individual consumers; internet hospital services through 1 Clinic, including online consultations, electronic prescriptions, and patient management; online wholesale pharmacy via 1 Drug Mall (also known as Yao Zhang Gui), serving pharmacies, clinics, and healthcare providers with pharmaceutical sourcing and supply chain solutions; cloud-based services for its extensive virtual pharmacy network; and omni-channel drug commercialization support for partners, encompassing digital marketing, patient education, data analytics, and pricing monitoring. Headquartered in Shanghai and founded in 2010 by Gang Yu and Junling Liu, 111, Inc. primarily serves the Chinese market with nationwide operations, employing around 1,238 people as of recent reports. Recent developments include sustained operational profitability for multiple consecutive quarters as of Q2 2025, with Q2 2024 marking income from operations of RMB3.3 million and positive cash flow; strategic partnerships such as a direct supply alliance with Beijing Scrianen Pharmaceutical in Q2 2024 to enhance drug distribution using big data and digital tools, an alliance named 1Pharmacy with ApicHope Pharmaceutical and others for innovative collaboration on exclusive products and traditional Chinese medicine, and agreements with Bayer Healthcare and Hainan Huluwa Pharmaceutical in 2024; acquisition of four new patents in 2024, increasing its total to 28 to bolster technological capabilities; and co-founders' strategic share purchases in September 2024 signaling confidence in growth amid ongoing digital transformation efforts.
111, Inc. Announces First Quarter 2026 Unaudited Financial Results
111, Inc. Announces First Quarter 2026 Unaudited Financial Results
111, Inc. Announces Fourth Quarter and Fiscal Year 2025 Financial Results
Reviewing 111 (NASDAQ:YI) & Hims & Hers Health (NYSE:HIMS)
Comparing Biotricity (OTCMKTS:BTCY) & 111 (NASDAQ:YI)
Head to Head Review: Veeva Systems (NYSE:VEEV) and 111 (NASDAQ:YI)
111, Inc. Announces Third Quarter 2025 Unaudited Financial Results
Head to Head Contrast: Privia Health Group (NASDAQ:PRVA) & 111 (NASDAQ:YI)
111, Inc. Announces Second Quarter 2025 Unaudited Financial Results
111, Inc. Announces First Quarter 2025 Unaudited Financial Results
111, Inc. (YI) Q4 2024 Earnings Call Transcript
111, Inc. Announces Fourth Quarter and Fiscal Year 2024 Financial Results
111, Inc. to Participate in Fireside Chat with Water Tower Research on March 26, 2025
111 to Announce Fourth Quarter and Fiscal Year 2024 Unaudited Financial Results on March 20, 2025 - Conference Call to Follow
111, Inc. Regains Compliance with NASDAQ Requirement
Compound Semiconductor Market to surpass USD 111.6 billion by 2032, Says Global Market Insights inc.
111, Inc. Announces ADS Ratio Change
111, Inc. (YI) Q3 2024 Earnings Call Transcript
111, Inc. Announces Third Quarter 2024 Unaudited Financial Results
111, Inc. to Participate in Fireside Chat with Water Tower Research on December 6, 2024